Quarterly report pursuant to Section 13 or 15(d)

Loss Per Share - Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details)

v3.20.2
Loss Per Share - Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Earnings Per Share [Abstract]        
Net loss - before noncontrolling interest $ (5,844) $ (3,739) $ (20,755) $ (7,443)
Net loss attributable to noncontrolling interest 266 145 702 314
Net loss - as reported, attributable to PAVmed Inc. (5,578) (3,594) (20,053) (7,129)
Series B Convertible Preferred Stock dividends: (71) (66) (141) (132)
Net loss attributable to PAVmed Inc. common stockholders $ (5,649) $ (3,660) $ (20,194) $ (7,261)
Weighted average common shares outstanding basic and diluted 44,781 27,606 44,140 27,344
Basic and diluted - Net loss - as reported, attributable to PAVmed Inc. $ (0.12) $ (0.13) $ (0.45) $ (0.26)
Basic and diluted - Net loss attributable to PAVmed Inc. common stockholders $ (0.13) $ (0.13) $ (0.46) $ (0.27)